Supplementary Figure S1 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer | Synapse
September 16, 2024
Supplementary Figure S1 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Key Points
Key points are not available for this paper at this time.
Abstract
Per patient ctDNA fractions and PSA levels at baseline and after 4 weeks of treatment